Table of Contents
What changed
Revenue fell 6.0% to $1,581.1m (down 9% in constant currency), with the decline concentrated in H1 as pandemic-era Hospital hardware demand normalised. H2 revenue recovered to $890.5m, up 14% reported and 12% in constant currency. Profit before tax dropped 34.9% to $328.0m and NPAT fell 33.6% to $250.3m, with the smaller NPAT decline reflecting a lower effective tax rate (23.7% versus 25.2%). Operating cash flow fell 26.5% to $238.2m while capex rose to $211.3m from $138.4m, compressing pre-lease free cash flow to $26.9m from $185.9m. The group remained in net cash, improving to $37.7m from $21.6m, and the final dividend lifted to 23.0cps from 22.5cps. Mix shifted: Homecare revenue grew to $553.8m (35.0% of group) while Hospital contracted to $1,020m (64.5% from 72.0%).
What matters
- Pre-lease FCF collapse. FCF fell from $185.9m to $26.9m, taking FCF/NPAT from 49.3% to 10.8% and leaving the lifted dividend at roughly 494% of pre-lease FCF this year. Capex intensity jumped to 13.4% of revenue from 8.2%, a level that needs to be read as a forward capacity bet rather than a run-rate cost.
- Earnings quality deterioration. PBT fell 34.9% on a 6.0% revenue decline, consistent with operating deleverage as high-margin Hospital hardware volumes receded. The supplied excerpts flag R&D at 11% of revenue (up from 9%), which points to operating cost growth outpacing revenue.
- Working-capital build. Receivable days lengthened to 41.5 from 31.0 and inventory days to 84.5 from 77.9, lifting operating working capital by $43.7m. Trade debtors rose 25.8% against a 6.0% revenue decline, which is the largest single quality flag in the result.
Expectations
No quantified FY24 guidance or forward-work target was disclosed in the supplied excerpts, so this briefing cannot test the result against management-stated ambitions. The shape context is constructive: H1 contributed only 43.7% of full-year revenue and 38.3% of NPAT, and the H2 return to 12% constant-currency growth suggests the Hospital hardware reset has largely washed through. FX remained a headwind, with constant-currency revenue declines 3 percentage points worse than reported at both the half and full-year. The release describes the strategy as "sustainable, profitable growth" without quantification.
Quality of result
The result is lower quality than the headlines suggest. Statutory NPAT outperformed PBT only because of a lower effective tax rate, so PBT's 34.9% decline is the cleaner read. Cash conversion deteriorated materially: operating cash flow covered only 72% of NPAT against 86% in FY22, and the $43.7m working-capital build — led by a 25.8% increase in receivables on falling revenue — is the primary driver. Capex of $211.3m took FCF close to break-even, so the 53.1% NPAT payout is effectively funded from the balance sheet this year rather than from in-period cash. The net cash position strengthened, but on cash alone ($121.0m vs $89.9m), with gross borrowings rising to $83.3m.
Unresolved
- What is the split between replacement/maintenance capex and capacity expansion in the $211.3m spend, and when does capex intensity normalise?
- Why did receivables grow 25.8% against a 6.0% revenue decline, and is any portion tied to slower-paying geographies or channels?
- Does H2's 12% constant-currency growth reflect a clean underlying rate, or is it still flattered by weak pcp comparatives in Hospital consumables?
- Gross margin direction is referenced in the excerpts but not quantified here; how much of the PBT compression is gross-margin versus opex-led?
- No FY24 revenue, margin or capex guidance was disclosed.
This briefing cannot assess segment profitability, gross margin movement, or management's forward-year operating assumptions because those disclosures are not in the supplied extraction.
Key metrics
| Metric | FY23 | FY22 | Change |
|---|---|---|---|
| Revenue | $1581.1m | $1681.7m | -6.0% ↓ |
| Net profit after tax | $250.3m | $376.9m | -33.6% ↓ |
| Net cash inflow from operating activities | $238.2m | $324.3m | -26.5% ↓ |
| Final dividend per share | 23.0c | 22.5c | +2.2% ↑ |
| Operating profit | $332.2m | $505.6m | -34.3% ↓ |
| Profit before tax | $328m | $504.2m | -34.9% ↓ |
| Cash and cash equivalents | $121m | $89.9m | +34.6% ↑ |
| Total assets | $2204.5m | $2107m | +4.6% ↑ |
Reference: annolyse.ai/briefings/fph-fy23
Segment breakdown
| Segment | Current revenue | Prior revenue | Current result | Mix shift |
|---|---|---|---|---|
| Hospital product group | $1020m | $1210m | — | -7.4pp |
| Homecare product group | $553.8m | $469.5m | — | +7.1pp |
Reference: annolyse.ai/briefings/fph-fy23
Analytical metrics
| Metric | FY23 | FY22 | Context |
|---|---|---|---|
| PBT growth | -35.0% | — | cleaner earnings measure |
| Effective tax rate | 23.7% | 25.3% | — |
| FCF pre-lease | $26.9m | $185.9m | −$159.0m |
| FCF / NPAT | 10.8% | 49.3% | complementary conversion metric |
| Capex % revenue | 13.4% | 8.2% | — |
| Capex | $211.3m | $138.4m | +$72.9m |
| Debtor days | 41.5 | 31.0 | +10.4 days |
| Inventory days | 84.5 | 77.9 | +6.6 days |
| Operating working capital | $545.4m | $501.7m | +$43.7m absorbed |
| Trade debtors | $179.6m | $142.8m | +$36.8m |
| Net debt | −$37.7m | −$21.6m | −$16.1m |
| Gross borrowings | $83.3m | $68.3m | +$15.0m |
| Payout ratio vs NPAT | 53.1% | — | — |
| Payout ratio vs FCF pre-lease | 494.3% | — | not covered |
| ROE (annualised) | 14.3% | 22.4% | Weakening |
| HY23 share of FY23 revenue | 43.7% | — | Other half was 56.3% |
| HY23 share of FY23 NPAT | 38.3% | — | Other half was 61.7% |
Reference: annolyse.ai/briefings/fph-fy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.